-
'Magic' Jalibert guides Bordeaux-Begles past Scarlets
-
Teenage pair Ndjantou and Mbaye star as PSG beat Metz to go top
-
Anglo-French star Jane Birkin gets name on bridge over Paris canal
-
US troops in Syria killed in alleged IS ambush
-
Jalibert masterclass guides Bordeaux-Begles past Scarlets
-
M23 marches on in east DR Congo as US vows action against Rwanda
-
Raphinha double stretches Barca's Liga lead in Osasuna win
-
Terrific Terrier returns Leverkusen to fourth
-
Colts activate 44-year-old Rivers for NFL game at Seattle
-
US troops in Syria killed in IS ambush attack
-
Liverpool's Slot says 'no issue to resolve' with Salah after outburst
-
'Stop the slaughter': French farmers block roads over cow disease cull
-
Stormers see off La Rochelle, Sale stun Clermont in Champions Cup
-
Maresca hails Palmer as Chelsea return to winning ways against Everton
-
Hungarian protesters demand Orban quits over abuse cases
-
Belarus frees protest leader Kolesnikova, Nobel winner Bialiatski
-
Salah sets up goal on return to Liverpool action
-
Palmer strikes as Chelsea return to winning ways against Everton
-
Pogacar targets Tour de France Paris-Roubaix and Milan-San Remo in 2026
-
Salah back in action for Liverpool after outburst
-
Atletico recover Liga momentum with battling win over Valencia
-
Meillard leads 'perfect' Swiss sweep in Val d'Isere giant slalom
-
Salah on Liverpool bench for Brighton match
-
Meillard leads Swiss sweep in Val d'Isere giant slalom
-
Indonesia flood death toll passes 1,000 as authorities ramp up aid
-
Cambodia shuts Thailand border crossings over deadly fighting
-
First urban cable car unveiled outside Paris
-
Vonn second behind Aicher in World Cup downhill at St Moritz
-
Aicher pips Vonn to downhill win at St Moritz
-
Thailand says 4 soldiers killed in Cambodia conflict, denies Trump truce claim
-
Fans vandalise India stadium after Messi's abrupt exit
-
Women sommeliers are cracking male-dominated wine world open
-
Exhibition of Franco-Chinese print master Zao Wou-Ki opens in Hong Kong
-
Myanmar junta denies killing civilians in hospital strike
-
Why SpaceX IPO plan is generating so much buzz
-
Thailand continues Cambodia strikes despite Trump truce calls
-
US envoy to meet Zelensky, Europe leaders in Berlin this weekend
-
North Korea acknowledges its troops cleared mines for Russia
-
US unseals warrant for tanker seized off Venezuelan coast
-
Cambodia says Thailand still bombing hours after Trump truce call
-
Machado urges pressure so Maduro understands 'he has to go'
-
Leinster stutter before beating Leicester in Champions Cup
-
World stocks mostly slide, consolidating Fed-fuelled gains
-
Crypto firm Tether bids for Juventus, is quickly rebuffed
-
Union sink second-placed Leipzig to climb in Bundesliga
-
US Treasury lifts sanctions on Brazil Supreme Court justice
-
UK king shares 'good news' that cancer treatment will be reduced in 2026
-
Wembanyama expected to return for Spurs in NBA Cup clash with Thunder
-
Five takeaways from Luigi Mangione evidence hearings
-
UK's king shares 'good news' that cancer treatment will be reduced in 2026
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
L.AbuAli--SF-PST